US20020183253A1 - Method of treating ocular neovascularization - Google Patents

Method of treating ocular neovascularization Download PDF

Info

Publication number
US20020183253A1
US20020183253A1 US10/080,797 US8079702A US2002183253A1 US 20020183253 A1 US20020183253 A1 US 20020183253A1 US 8079702 A US8079702 A US 8079702A US 2002183253 A1 US2002183253 A1 US 2002183253A1
Authority
US
United States
Prior art keywords
endostatin
individual
vector
administered
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/080,797
Other languages
English (en)
Inventor
Romulus Brazzell
Peter Campochiaro
Katharine Dixon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/080,797 priority Critical patent/US20020183253A1/en
Publication of US20020183253A1 publication Critical patent/US20020183253A1/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KALEKO, MICHAEL, LUO, TIANCI
Priority to US12/785,461 priority patent/US8338384B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRAZZELL, ROMULUS K, DIXON, KATHARINE, CAMPOCHIARO, PETER A
Priority to US13/716,925 priority patent/US9238057B2/en
Assigned to WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT reassignment WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT SECURITY AGREEMENT Assignors: WELLSTAT OPHTHALMICS CORPORATION
Assigned to PDL BIOPHARMA, INC. reassignment PDL BIOPHARMA, INC. SECURITY AGREEMENT Assignors: WELLSTAT OPHTHALMICS CORPORATION
Assigned to WELLSTAT OPHTHALMICS CORPORATION reassignment WELLSTAT OPHTHALMICS CORPORATION RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
US10/080,797 2001-02-22 2002-02-21 Method of treating ocular neovascularization Abandoned US20020183253A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/080,797 US20020183253A1 (en) 2001-02-22 2002-02-21 Method of treating ocular neovascularization
US12/785,461 US8338384B2 (en) 2001-02-22 2010-05-23 Method for treating ocular neovascularization
US13/716,925 US9238057B2 (en) 2001-02-22 2012-12-17 Method for treating ocular neovascularization

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27078701P 2001-02-22 2001-02-22
US28129601P 2001-04-04 2001-04-04
US10/080,797 US20020183253A1 (en) 2001-02-22 2002-02-21 Method of treating ocular neovascularization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/785,461 Continuation US8338384B2 (en) 2001-02-22 2010-05-23 Method for treating ocular neovascularization

Publications (1)

Publication Number Publication Date
US20020183253A1 true US20020183253A1 (en) 2002-12-05

Family

ID=26954498

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/080,797 Abandoned US20020183253A1 (en) 2001-02-22 2002-02-21 Method of treating ocular neovascularization
US12/785,461 Expired - Lifetime US8338384B2 (en) 2001-02-22 2010-05-23 Method for treating ocular neovascularization
US13/716,925 Expired - Fee Related US9238057B2 (en) 2001-02-22 2012-12-17 Method for treating ocular neovascularization

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/785,461 Expired - Lifetime US8338384B2 (en) 2001-02-22 2010-05-23 Method for treating ocular neovascularization
US13/716,925 Expired - Fee Related US9238057B2 (en) 2001-02-22 2012-12-17 Method for treating ocular neovascularization

Country Status (5)

Country Link
US (3) US20020183253A1 (ja)
EP (1) EP1401480B1 (ja)
JP (1) JP4689144B2 (ja)
AU (1) AU2002240463A1 (ja)
WO (1) WO2002067971A2 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115902A1 (en) * 2001-02-22 2002-08-22 Dejuan Eugene Beta radiotherapy emitting surgical device and methods of use thereof
US20040234505A1 (en) * 1998-09-23 2004-11-25 Stuart Naylor Polynucleotide constructs and uses thereof
US20060251621A1 (en) * 2002-09-27 2006-11-09 Campochiaro Peter A Ocular gene therapy
US20070104684A1 (en) * 2002-08-28 2007-05-10 Campochiaro Peter A Ocular gene therapy
US20090148936A1 (en) * 2000-12-19 2009-06-11 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
US7744520B2 (en) 2004-02-12 2010-06-29 Neovista, Inc. Method and apparatus for intraocular brachytherapy
US7803103B2 (en) 2005-02-11 2010-09-28 Neovista Inc. Methods and apparatus for intraocular brachytherapy
US8353812B2 (en) 2008-06-04 2013-01-15 Neovista, Inc. Handheld radiation delivery system

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401480B1 (en) 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization
WO2003066810A2 (en) * 2002-02-04 2003-08-14 Novartis Ag Recombinant bovine immunodeficiency virus based gene transfer system
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
GB0402100D0 (en) * 2004-01-30 2004-03-03 Novartis Ag Organic compounds
DK1767545T3 (da) 2005-09-22 2010-03-15 Biocompatibles Uk Ltd GLP-1 (Glucagon-lignende peptid-1)-fusionspolypeptider med forøget peptidaseresistens
ATE444741T1 (de) 2006-05-10 2009-10-15 Biocompatibles Uk Ltd Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
EP2251028A1 (en) * 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor
CN104548067A (zh) * 2014-12-23 2015-04-29 浙江省人民医院 重组人血管内皮抑制素在制备治疗眼表新生血管性疾病药物中的应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827702A (en) * 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
US6174861B1 (en) * 1996-10-22 2001-01-16 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
US20020114783A1 (en) * 2000-12-19 2002-08-22 Binoy Appukuttan Lentiviral vector-mediated gene transfer and uses thereof
US20020127595A1 (en) * 1995-10-23 2002-09-12 O'reilly Michael S. Methods of detecting endostatin protein
US6555107B2 (en) * 1997-09-24 2003-04-29 The Regents Of The University Of California Lentiviral nucleic acids and uses thereof
US20030082159A1 (en) * 2000-12-19 2003-05-01 Binoy Appukuttan Lentiviral vector-mediated gene transfer and uses thereof
US6638502B1 (en) * 1997-04-28 2003-10-28 Gencell Sas Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
US6921749B1 (en) * 1999-04-15 2005-07-26 Universita' Degli Studi Di Milano Polypeptides derived from endostatin exhibiting antiangiogenic activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545423A (en) * 1991-11-25 1996-08-13 Vivorx, Inc. Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
WO1994012161A1 (en) * 1992-11-24 1994-06-09 Clover Consolidated, Limited Cytoprotective, biocompatible, retrievable macrocapsules
WO1999026480A1 (en) * 1997-11-20 1999-06-03 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
US7125542B2 (en) * 2000-02-10 2006-10-24 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
AU2002224403A1 (en) * 2000-10-13 2002-04-22 Entremed, Inc Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
EP1401480B1 (en) 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827702A (en) * 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US20020127595A1 (en) * 1995-10-23 2002-09-12 O'reilly Michael S. Methods of detecting endostatin protein
US6174861B1 (en) * 1996-10-22 2001-01-16 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
US6638502B1 (en) * 1997-04-28 2003-10-28 Gencell Sas Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
US6555107B2 (en) * 1997-09-24 2003-04-29 The Regents Of The University Of California Lentiviral nucleic acids and uses thereof
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
US6921749B1 (en) * 1999-04-15 2005-07-26 Universita' Degli Studi Di Milano Polypeptides derived from endostatin exhibiting antiangiogenic activity
US20020114783A1 (en) * 2000-12-19 2002-08-22 Binoy Appukuttan Lentiviral vector-mediated gene transfer and uses thereof
US20030082159A1 (en) * 2000-12-19 2003-05-01 Binoy Appukuttan Lentiviral vector-mediated gene transfer and uses thereof
US7122181B2 (en) * 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234505A1 (en) * 1998-09-23 2004-11-25 Stuart Naylor Polynucleotide constructs and uses thereof
US20090148936A1 (en) * 2000-12-19 2009-06-11 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
US8100818B2 (en) 2001-02-22 2012-01-24 TDH Partners, Inc. Beta radiotherapy emitting surgical device and methods of use thereof
US6875165B2 (en) 2001-02-22 2005-04-05 Retinalabs, Inc. Method of radiation delivery to the eye
US20020115902A1 (en) * 2001-02-22 2002-08-22 Dejuan Eugene Beta radiotherapy emitting surgical device and methods of use thereof
US20070104684A1 (en) * 2002-08-28 2007-05-10 Campochiaro Peter A Ocular gene therapy
US20060251621A1 (en) * 2002-09-27 2006-11-09 Campochiaro Peter A Ocular gene therapy
US7744520B2 (en) 2004-02-12 2010-06-29 Neovista, Inc. Method and apparatus for intraocular brachytherapy
US7951060B2 (en) 2004-02-12 2011-05-31 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
US7803102B2 (en) 2004-02-12 2010-09-28 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
US8365721B2 (en) 2004-02-12 2013-02-05 Neovista Inc. Methods and apparatus for intraocular brachytherapy
US7803103B2 (en) 2005-02-11 2010-09-28 Neovista Inc. Methods and apparatus for intraocular brachytherapy
US8292795B2 (en) 2005-02-11 2012-10-23 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
US8353812B2 (en) 2008-06-04 2013-01-15 Neovista, Inc. Handheld radiation delivery system

Also Published As

Publication number Publication date
AU2002240463A1 (en) 2002-09-12
US20100286253A1 (en) 2010-11-11
WO2002067971A2 (en) 2002-09-06
JP2004527494A (ja) 2004-09-09
WO2002067971A3 (en) 2003-12-31
US20130165503A1 (en) 2013-06-27
EP1401480A2 (en) 2004-03-31
EP1401480B1 (en) 2012-11-28
US8338384B2 (en) 2012-12-25
JP4689144B2 (ja) 2011-05-25
US9238057B2 (en) 2016-01-19

Similar Documents

Publication Publication Date Title
US9238057B2 (en) Method for treating ocular neovascularization
US7989426B2 (en) Selective induction of apoptosis to treat ocular disease by expression of PEDF
US20070098692A1 (en) Materials and methods for treating ocular-related disorders
AU2004245175B2 (en) Improved secretion of neublastin
JP2002502608A (ja) 血管新生促進因子である血管内皮細胞成長因子：ｖｅｇｆの変異体
US20090018100A1 (en) Materials and methods for treating ocular-related disorders
US20040086494A1 (en) Immune privileged cells for delivery of proteins and peptides
AU780634C (en) Gene Therapy for treating ocular-related disorders
US20060251621A1 (en) Ocular gene therapy
EP1937295A2 (en) Treatment of retinopathies using gfr 3 agonists
JP3920928B2 (ja) 移植片拒絶反応の防止法および普遍的遺伝子治療宿主細胞の生産法
Chaum et al. Gene therapy for genetic and acquired retinal diseases
EP1534751B1 (en) Ocular gene therapy
WO1999003999A1 (en) Methods and compositions for inhibiting the proinflammatory response
EP1170373A1 (en) Peptide-mediated ocular cell transfection
US20100003264A1 (en) Reduction of Ophthalmalogic Neovascularization

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KALEKO, MICHAEL;LUO, TIANCI;REEL/FRAME:017830/0244

Effective date: 20060324

AS Assignment

Owner name: NOVARTIS AG,SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRAZZELL, ROMULUS K;CAMPOCHIARO, PETER A;DIXON, KATHARINE;SIGNING DATES FROM 20020404 TO 20020530;REEL/FRAME:024426/0743

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE

Free format text: SECURITY AGREEMENT;ASSIGNOR:WELLSTAT OPHTHALMICS CORPORATION;REEL/FRAME:031030/0720

Effective date: 20130801

AS Assignment

Owner name: PDL BIOPHARMA, INC., NEVADA

Free format text: SECURITY AGREEMENT;ASSIGNOR:WELLSTAT OPHTHALMICS CORPORATION;REEL/FRAME:031227/0182

Effective date: 20130820

AS Assignment

Owner name: WELLSTAT OPHTHALMICS CORPORATION, MARYLAND

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:054983/0577

Effective date: 20210108